Aurobindo’s CuraTeQ Withdraws European Biosimilars – But They Will Be Back
EMA Refiling Expected After Filgrastim And Pegfilgrastim Applications Withdrawn
Executive Summary
Aurobindo’s CuraTeQ has withdrawn EMA filings for its filgrastim and pegfilgrastim biosimilars over inspection timing issues – but expects to refile the products as it works towards obtaining the necessary EU GMP certification.